Last reviewed · How we verify
intravenous crystalloid fluid, 500 mL
At a glance
| Generic name | intravenous crystalloid fluid, 500 mL |
|---|---|
| Sponsor | Louisiana State University Health Sciences Center in New Orleans |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis (NA)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Effect of Giving Reduced Fluid in Children After Trauma (NA)
- Effect of Enhanced Recovery After Surgery for Benign Anorectal Conditions (NA)
- Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure (PHASE3)
- Evaluation of Blood Sampling From a Pre-existed Peripheral Intravenous Catheter Line (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: